Symbols / ALXO Stock $1.63 +6.54% ALX Oncology Holdings Inc.

Healthcare • Biotechnology • United States • NMS
ALXO (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Jason W. Lettmann
Exch · Country NMS · United States
Market Cap 219.34M
Enterprise Value 92.06M
Income -88.87M
Sales —
FCF (ttm) -47.77M
Book/sh 1.12
Cash/sh 1.04
Employees 43
Insider 10d —
IPO Jul 17, 2020
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -3.03
PEG —
P/S —
P/B 1.45
P/C —
EV/EBITDA -1.05
EV/Sales —
Quick Ratio 7.00
Current Ratio 7.21
Debt/Eq 8.62
LT Debt/Eq —
EPS (ttm) -1.49
EPS next Y -0.54
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-08
Earnings (prior) 2026-05-08
ROA -36.76%
ROE -74.17%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 134.56M
Shs Float 77.45M
Insider Own 0.92%
Instit Own 78.77%
Short Float 1.41%
Short Ratio 1.82
Short Interest 1.71M
52W High 2.66
vs 52W High -38.72%
52W Low 0.40
vs 52W Low 303.47%
Beta 0.45
Impl. Vol. 37.50%
Rel Volume 0.83
Avg Volume 1.14M
Volume 949.62K
Target (mean) $4.60
Tgt Median $4.00
Tgt Low $4.00
Tgt High $6.00
# Analysts 5
Recom None
Prev Close $1.53
Price $1.63
Change 6.54%
About

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$4.60
Mean price target
2. Current target
$1.63
Latest analyst target
3. DCF / Fair value
$-6.39
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.63
Low
$4.00
High
$6.00
Mean
$4.60

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-19 init Wells Fargo — → Overweight $5
2026-03-10 reit HC Wainwright & Co. Buy → Buy $4
2026-02-05 main Piper Sandler Overweight → Overweight $4
2025-05-21 main UBS Buy → Buy $1
2025-05-09 main HC Wainwright & Co. Buy → Buy $2
2025-03-07 main Stifel Hold → Hold $2
2025-03-07 reit HC Wainwright & Co. Buy → Buy $5
2025-03-06 main Piper Sandler Overweight → Overweight $9
2025-03-06 up Jefferies Hold → Buy $3
2025-01-27 main UBS Buy → Buy $2
2025-01-24 reit Cantor Fitzgerald Overweight → Overweight —
2025-01-24 main HC Wainwright & Co. Buy → Buy $5
2024-12-19 down Jefferies Buy → Hold $2
2024-12-18 reit Cantor Fitzgerald Overweight → Overweight —
2024-12-18 reit HC Wainwright & Co. Buy → Buy $25
2024-11-12 reit Cantor Fitzgerald — → Overweight —
2024-08-16 main UBS Buy → Buy $4
2024-08-13 reit HC Wainwright & Co. Buy → Buy $25
2024-08-12 reit Cantor Fitzgerald — → Overweight —
2024-08-09 reit Stifel Hold → Hold $3
News
RSS: Latest ALXO news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-19 LETTMANN JASON Chief Executive Officer — 12,311 $2.17 $26,715
2026-03-19 PINTO SHELLY Officer — 903 $2.17 $1,960
2026-02-18 PINTO SHELLY Officer — 565 $2.27 $1,283
2026-02-02 GOODMAN COREY S Director and Beneficial Owner of more than 10% of a Class of Security — 3,184,713 $1.57 $4,999,999
2026-01-06 PINTO SHELLY Officer — 3,925 $1.11 $4,357
2025-09-17 LETTMANN JASON Chief Executive Officer — 92,233 $1.07 $99,352
2025-08-18 SHANTHARAM HARISH Chief Financial Officer — 75,000 $0.78 $58,402
2025-08-15 LETTMANN JASON Chief Executive Officer — 2,382 $0.64 $1,525
2025-08-15 PINTO SHELLY Officer — 611 $0.64 $391
2025-07-07 PINTO SHELLY Officer — 2,011 $0.45 $905
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Cost Of Revenue
—
—
—
0.00
Reconciled Cost Of Revenue
—
—
—
0.00
Gross Profit
—
—
—
0.00
Operating Expense
100.85
-29.21%
142.47
-16.33%
170.28
+33.62%
127.44
Research And Development
77.00
-33.84%
116.37
-17.93%
141.79
+44.10%
98.40
Selling General And Administration
23.85
-8.60%
26.09
-8.39%
28.48
-1.90%
29.04
General And Administrative Expense
23.85
-8.60%
26.09
-8.39%
28.48
-1.90%
29.04
Salaries And Wages
15.05
-7.25%
16.22
-13.29%
18.71
-0.83%
18.86
Other Gand A
8.80
-10.82%
9.87
+0.99%
9.78
-3.89%
10.17
Total Expenses
100.85
-29.21%
142.47
-16.33%
170.28
+33.62%
127.44
Operating Income
-100.85
+29.21%
-142.47
+16.33%
-170.28
-33.62%
-127.44
Total Operating Income As Reported
-104.02
+26.99%
-142.47
+16.33%
-170.28
-33.62%
-127.44
EBITDA
-99.39
+24.85%
-132.25
+16.51%
-158.40
-28.95%
-122.84
Normalized EBITDA
-96.21
+27.25%
-132.25
+16.51%
-158.40
-28.95%
-122.84
Reconciled Depreciation
0.71
-19.04%
0.87
+4.31%
0.84
+144.44%
0.34
EBIT
-100.09
+24.81%
-133.12
+16.40%
-159.24
-29.27%
-123.18
Total Unusual Items
-3.17
0.00
0.00
0.00
Total Unusual Items Excluding Goodwill
-3.17
0.00
0.00
0.00
Special Income Charges
-3.17
0.00
0.00
0.00
Write Off
3.17
0.00
0.00
—
Net Income
-101.69
+24.59%
-134.85
+16.14%
-160.81
-30.23%
-123.48
Pretax Income
-101.69
+24.59%
-134.85
+16.14%
-160.81
-30.29%
-123.42
Net Non Operating Interest Income Expense
2.36
-69.07%
7.64
-15.93%
9.08
+124.85%
4.04
Interest Expense Non Operating
1.60
-7.35%
1.73
+10.48%
1.56
+557.56%
0.24
Net Interest Income
2.36
-69.07%
7.64
-15.93%
9.08
+124.85%
4.04
Interest Expense
1.60
-7.35%
1.73
+10.48%
1.56
+557.56%
0.24
Interest Income Non Operating
3.96
-57.68%
9.37
-12.05%
10.65
+148.92%
4.28
Interest Income
3.96
-57.68%
9.37
-12.05%
10.65
+148.92%
4.28
Other Income Expense
-3.21
-15955.00%
-0.02
-105.14%
0.39
+1868.18%
-0.02
Other Non Operating Income Expenses
-0.04
-80.00%
-0.02
-105.14%
0.39
+1868.18%
-0.02
Tax Provision
0.00
0.00
0.00
-100.00%
0.06
Tax Rate For Calcs
0.00
0.00
0.00
-100.00%
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-101.69
+24.59%
-134.85
+16.14%
-160.81
-30.23%
-123.48
Net Income From Continuing Operation Net Minority Interest
-101.69
+24.59%
-134.85
+16.14%
-160.81
-30.23%
-123.48
Net Income From Continuing And Discontinued Operation
-101.69
+24.59%
-134.85
+16.14%
-160.81
-30.23%
-123.48
Net Income Continuous Operations
-101.69
+24.59%
-134.85
+16.14%
-160.81
-30.23%
-123.48
Normalized Income
-98.52
+26.94%
-134.85
+16.14%
-160.81
-30.23%
-123.48
Net Income Common Stockholders
-101.69
+24.59%
-134.85
+16.14%
-160.81
-30.23%
-123.48
Diluted EPS
-1.90
+26.36%
-2.58
+31.02%
-3.74
-23.43%
-3.03
Basic EPS
-1.90
+26.36%
-2.58
+31.02%
-3.74
-23.43%
-3.03
Basic Average Shares
53.66
+2.84%
52.17
+21.37%
42.99
+5.62%
40.70
Diluted Average Shares
53.66
+2.84%
52.17
+21.37%
42.99
+5.62%
40.70
Diluted NI Availto Com Stockholders
-101.69
+24.59%
-134.85
+16.14%
-160.81
-30.23%
-123.48
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
59.05
-60.04%
147.78
-39.08%
242.55
-20.86%
306.49
Current Assets
50.73
-62.24%
134.35
-28.79%
188.66
-30.38%
270.97
Cash Cash Equivalents And Short Term Investments
44.79
-64.94%
127.76
-30.09%
182.74
-31.36%
266.21
Cash And Cash Equivalents
16.37
-6.80%
17.57
-21.60%
22.41
-54.11%
48.82
Other Short Term Investments
28.42
-74.21%
110.19
-31.27%
160.33
-26.25%
217.38
Receivables
0.30
-66.59%
0.89
—
—
Accrued Interest Receivable
0.30
-66.59%
0.89
—
—
Prepaid Assets
5.62
-1.00%
5.68
—
—
Other Current Assets
0.02
-25.93%
0.03
-99.54%
5.92
+24.38%
4.76
Total Non Current Assets
8.32
-38.02%
13.42
-75.09%
53.89
+51.73%
35.52
Net PPE
3.87
-59.80%
9.63
-11.15%
10.84
+10.48%
9.81
Gross PPE
5.85
-50.03%
11.71
-3.06%
12.08
+18.23%
10.22
Accumulated Depreciation
-1.98
+4.72%
-2.08
-67.91%
-1.24
-206.95%
-0.40
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
0.63
-1.88%
0.64
+10.00%
0.58
+13.73%
0.51
Other Properties
4.52
-47.26%
8.56
-4.71%
8.98
+22.31%
7.35
Leases
0.71
-71.74%
2.51
-0.16%
2.51
+6.48%
2.36
Investments And Advances
3.49
-0.85%
3.52
-90.05%
35.41
+112.05%
16.70
Non Current Accounts Receivable
—
—
—
0.08
Non Current Prepaid Assets
0.80
+1100.00%
0.07
-99.10%
7.44
-14.66%
8.72
Other Non Current Assets
0.15
-25.50%
0.20
+0.00%
0.20
-30.56%
0.29
Total Liabilities Net Minority Interest
33.06
-3.20%
34.16
-35.36%
52.84
+22.81%
43.02
Current Liabilities
24.55
+32.72%
18.50
-48.61%
36.00
+27.10%
28.32
Payables And Accrued Expenses
12.66
+24.26%
10.19
-63.27%
27.73
+22.87%
22.57
Payables
4.91
+5.77%
4.65
-49.14%
9.13
-6.06%
9.72
Accounts Payable
4.91
+9.27%
4.50
-47.65%
8.59
+6.42%
8.07
Other Payable
—
—
—
—
Current Accrued Expenses
7.74
+39.77%
5.54
-70.21%
18.59
+44.78%
12.84
Pensionand Other Post Retirement Benefit Plans Current
4.36
-17.90%
5.31
-12.54%
6.07
+63.62%
3.71
Total Tax Payable
—
—
—
—
Income Tax Payable
—
—
—
—
Current Debt And Capital Lease Obligation
5.22
+1099.31%
0.43
-72.38%
1.57
+51.30%
1.04
Current Debt
5.22
+1099.31%
0.43
—
—
Other Current Borrowings
5.22
+1099.31%
0.43
—
—
Current Capital Lease Obligation
—
—
1.57
+51.30%
1.04
Other Current Liabilities
2.32
-9.72%
2.57
+16.69%
2.21
+7.56%
2.05
Total Non Current Liabilities Net Minority Interest
8.51
-45.63%
15.66
-7.02%
16.84
+14.56%
14.70
Long Term Debt And Capital Lease Obligation
4.53
-52.14%
9.47
-1.76%
9.64
+2.66%
9.39
Long Term Debt
4.53
-52.14%
9.47
-1.76%
9.64
+2.66%
9.39
Long Term Capital Lease Obligation
—
—
5.98
—
Other Non Current Liabilities
3.98
-35.68%
6.19
-14.07%
7.20
+35.59%
5.31
Stockholders Equity
25.98
-77.13%
113.62
-40.11%
189.71
-27.99%
263.46
Common Stock Equity
25.98
-77.13%
113.62
-40.11%
189.71
-27.99%
263.46
Capital Stock
0.05
+1.89%
0.05
+6.00%
0.05
+21.95%
0.04
Common Stock
0.05
+1.89%
0.05
+6.00%
0.05
+21.95%
0.04
Share Issued
54.39
+2.52%
53.05
+6.21%
49.95
+22.25%
40.86
Ordinary Shares Number
54.39
+2.52%
53.05
+6.21%
49.95
+22.25%
40.86
Additional Paid In Capital
748.72
+1.95%
734.41
+8.69%
675.68
+14.57%
589.74
Retained Earnings
-722.82
-16.37%
-621.12
-27.73%
-486.27
-49.41%
-325.47
Gains Losses Not Affecting Retained Earnings
0.03
-89.82%
0.28
+7.42%
0.26
+130.30%
-0.84
Other Equity Adjustments
0.03
-89.82%
0.28
+7.42%
0.26
+130.30%
-0.84
Total Equity Gross Minority Interest
25.98
-77.13%
113.62
-40.11%
189.71
-27.99%
263.46
Total Capitalization
30.51
-75.21%
123.09
-38.26%
199.35
-26.94%
272.85
Working Capital
26.17
-77.41%
115.85
-24.11%
152.66
-37.09%
242.64
Invested Capital
35.73
-71.07%
123.52
-38.04%
199.35
-26.94%
272.85
Total Debt
9.75
-1.57%
9.90
+2.75%
9.64
+2.66%
9.39
Capital Lease Obligations
—
—
7.56
+626.03%
1.04
Net Tangible Assets
25.98
-77.13%
113.62
-40.11%
189.71
-27.99%
263.46
Tangible Book Value
25.98
-77.13%
113.62
-40.11%
189.71
-27.99%
263.46
Available For Sale Securities
3.49
-0.85%
3.52
-90.05%
35.41
+112.05%
16.70
Dueto Related Parties Current
0.00
-100.00%
0.15
-72.56%
0.54
-67.09%
1.65
Investmentin Financial Assets
3.49
-0.85%
3.52
-90.05%
35.41
+112.05%
16.70
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-84.14
+30.98%
-121.91
+6.48%
-130.36
-46.11%
-89.22
Cash Flow From Continuing Operating Activities
-84.14
+30.98%
-121.91
+6.48%
-130.36
-46.11%
-89.22
Net Income From Continuing Operations
-101.69
+24.59%
-134.85
+16.14%
-160.81
-30.23%
-123.48
Depreciation Amortization Depletion
0.71
-19.04%
0.87
+4.31%
0.84
+144.44%
0.34
Depreciation And Amortization
0.71
-19.04%
0.87
+4.31%
0.84
+144.44%
0.34
Other Non Cash Items
2.00
-2.49%
2.05
+34.69%
1.52
+30.31%
1.17
Stock Based Compensation
12.58
-53.57%
27.09
+3.12%
26.27
+10.21%
23.84
Asset Impairment Charge
3.17
0.00
—
—
Operating Gains Losses
—
0.01
—
—
Gain Loss On Sale Of PPE
0.00
-100.00%
0.01
0.00
0.00
Change In Working Capital
0.34
+102.70%
-12.43
-249.81%
8.30
-15.77%
9.85
Change In Receivables
—
—
—
0.00
Change In Prepaid Assets
0.66
+195.09%
-0.69
+46.40%
-1.29
+12.53%
-1.48
Change In Payables And Accrued Expense
2.27
+113.34%
-17.04
-261.15%
10.57
-8.47%
11.55
Change In Accrued Expense
2.00
+115.86%
-12.62
-212.47%
11.22
+59.73%
7.03
Change In Payable
0.27
+106.16%
-4.42
-580.74%
-0.65
-114.34%
4.53
Change In Account Payable
0.27
+106.16%
-4.42
-580.74%
-0.65
-114.34%
4.53
Change In Other Current Assets
-0.69
-109.30%
7.38
+439.90%
1.37
+82.13%
0.75
Change In Other Current Liabilities
-1.91
+7.77%
-2.07
+11.98%
-2.35
-140.84%
-0.98
Investing Cash Flow
82.59
-4.25%
86.26
+93.15%
44.66
+118.97%
-235.42
Cash Flow From Continuing Investing Activities
82.59
-4.25%
86.26
+93.15%
44.66
+118.97%
-235.42
Net PPE Purchase And Sale
-0.21
+52.57%
-0.45
+64.91%
-1.27
+10.72%
-1.43
Purchase Of PPE
-0.21
+52.57%
-0.45
+64.91%
-1.27
+10.72%
-1.43
Capital Expenditure
-0.21
+52.57%
-0.45
+64.91%
-1.27
+10.72%
-1.43
Net Investment Purchase And Sale
82.80
-4.50%
86.70
+88.77%
45.93
+119.63%
-233.99
Purchase Of Investment
-51.59
+51.96%
-107.41
+56.45%
-246.63
+34.54%
-376.79
Sale Of Investment
134.39
-30.77%
194.11
-33.65%
292.56
+104.87%
142.80
Net Intangibles Purchase And Sale
—
—
0.00
0.00
Purchase Of Intangibles
—
—
0.00
0.00
Financing Cash Flow
0.36
-98.83%
30.82
-48.02%
59.29
+501.33%
9.86
Cash Flow From Continuing Financing Activities
0.36
-98.83%
30.82
-48.02%
59.29
+501.33%
9.86
Net Issuance Payments Of Debt
-1.36
-64.93%
-0.83
-113.14%
-0.39
-104.04%
9.61
Issuance Of Debt
—
0.00
0.00
-100.00%
10.00
Repayment Of Debt
-1.36
-64.93%
-0.83
-113.14%
-0.39
+0.00%
-0.39
Long Term Debt Issuance
—
0.00
0.00
-100.00%
10.00
Long Term Debt Payments
-1.36
-64.93%
-0.83
-113.14%
-0.39
+0.00%
-0.39
Net Long Term Debt Issuance
-1.36
-64.93%
-0.83
-113.14%
-0.39
-104.04%
9.61
Net Common Stock Issuance
0.00
0.00
-100.00%
58.89
0.00
Proceeds From Stock Option Exercised
0.04
-98.08%
1.98
+150.38%
0.79
-12.29%
0.90
Net Other Financing Charges
1.69
-94.31%
29.66
—
-0.66
Changes In Cash
-1.19
+75.33%
-4.84
+81.68%
-26.42
+91.61%
-314.78
Beginning Cash Position
17.63
-21.53%
22.47
-54.03%
48.89
-86.56%
363.67
End Cash Position
16.44
-6.77%
17.63
-21.53%
22.47
-54.03%
48.89
Free Cash Flow
-84.35
+31.06%
-122.36
+7.05%
-131.64
-45.22%
-90.65
Interest Paid Supplemental Data
1.26
-9.23%
1.39
+17.84%
1.18
+1042.72%
0.10
Income Tax Paid Supplemental Data
—
—
0.00
0.00
Amortization Of Securities
-1.24
+73.33%
-4.66
+28.21%
-6.49
-590.11%
-0.94
Common Stock Issuance
0.00
0.00
-100.00%
58.89
0.00
Issuance Of Capital Stock
0.00
0.00
-100.00%
58.89
0.00
Net Preferred Stock Issuance
—
—
—
0.00
Preferred Stock Issuance
—
—
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category